In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7

References

• Abbott FV, Palmour RA. (1988). Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci 43:1685–95
   PubMed Web of Science ®Google Scholar
• Barbier O, Turgeon D, Girard C, et al. (2000). 3′-Azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28:497–502
   PubMed Web of Science ®Google Scholar
• Chang R. (2005). Enzyme inhibition. In: Physical chemistry for the biosciences. Herndon (VA): University Science Books, 377–85
   Google Scholar
• Court MH, Krishnaswamy S, Hao Q, et al. (2003). Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125–33
   PubMed Web of Science ®Google Scholar
• Court MH, Zhang X, Ding X, et al. (2012). Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42:266–77
   PubMed Web of Science ®Google Scholar
• Dong RH, Fang ZZ, Zhu LL, et al. (2012). Investigation of UDP-glucuronosyltransferases (UGTs) inhibitory properties of carvacrol. Phytother Res 26:86–90
   PubMed Web of Science ®Google Scholar
• Evans DF, Pye G, Bramley R, et al. (1988). Measurement of gastrointestinal pH profiles in normal ambulant subjects. Gut 29:1035–41
   PubMed Web of Science ®Google Scholar
• Fallingborg J. (1999). Intraluminal pH of the human gastrointestinal tract. Danish Med Bull 46:183–95
   PubMed Web of Science ®Google Scholar
• Green MD, Bishop WP, Tephly TR. (1995). Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 23:299–302
   PubMed Web of Science ®Google Scholar
• Holthe M, Rakvag TN, Klepstad P, et al. (2003). Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 3:17–26
   PubMed Web of Science ®Google Scholar
• Huang SM, Zhang L. (2012). Draft guidance/guidance for industry. Drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Silver Spring (MD): Center for Drug Evaluation and Research (CDER)
   Google Scholar
• Huskey SW, Dean BJ, Doss GA, et al. (2004). The metabolic disposition of aprepitant, A substance p receptor antagonist, in rats and dogs. Drug Metab Dispos 32:246–58
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Tracy TS. (2002). Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355–62
   PubMed Web of Science ®Google Scholar
• Innocenti F, Iyer L, Ramírez J, et al. (2001). Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686–92
   PubMed Web of Science ®Google Scholar
• Kaivosaari S, Finel M, Koskinen M. (2011). N-Glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica 41:652–69
   PubMed Web of Science ®Google Scholar
• Kamdem LK, Liu Y, Stearns V, et al. (2010). In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 70:854–69
   PubMed Web of Science ®Google Scholar
• King CD, Rios MD, Green MD, Tephly TR. (2000). UDP-glucuronosyltranferases. Curr Drug Metab 1:143–61
   PubMed Web of Science ®Google Scholar
• Lasseter KC, Gambale J, Jin B, et al. (2007). Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47:834–40
   PubMed Web of Science ®Google Scholar
• Lennernas H. (2007). Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37:1015–51
   PubMed Web of Science ®Google Scholar
• Liu Y, Ramirez J, House L, Ratain MJ. (2010). Comparison of the drug–drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 38:32–9
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (2003). Emend [package insert]. Whitehouse Station, NJ
   Google Scholar
• Nakamura A, Nakajima M, Yamanaka H, et al. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461–4
   PubMed Web of Science ®Google Scholar
• Nakajima M, Tanaka E, Kobayashi T, et al. (2002). Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 30:636–42
   PubMed Web of Science ®Google Scholar
• Olver IN. (2004). Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting. Int J Clin Pract 58:201–6
   PubMed Web of Science ®Google Scholar
• Sanchez RI, Wang RW, Newton DJ, et al. (2004). Cytochrome P450 is the major enzyme involved in the metabolism of the substance p receptor antagonist aprepitant. Drug Metab Dispos 32:1287–92
   PubMed Web of Science ®Google Scholar
• Sawyer MB, Innocenti F, Das S, et al. (2003). A pharmacogenetic study of uridine diphosphate-glucurosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73:566–74
   PubMed Web of Science ®Google Scholar
• Shadle CR, Lee Y, Majumdar AK, et al. (2004). Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44:215–23
   PubMed Web of Science ®Google Scholar
• Takahashi T, Nakamura Y, Tsuya A, et al. (2011). Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol 68:653–9
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006). Selectivity of substrate (triflouperazine) and inhibitor (amytriptylene, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for human UDP-glucurosyltransferases. Drug Metab Dispos 34:449–56
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Mackenzie PI, Guo XH, et al. (2004). Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413–23
   PubMed Web of Science ®Google Scholar
• Veal GJ, Back DJ. (1995). Metabolism of zidovudine. Gen Pharm 26:1469–75
   PubMedGoogle Scholar
• Walsky RL, Bauman JN, Bourcier K, et al. (2012). Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos 40:1051–65
   PubMed Web of Science ®Google Scholar
• Wang X, Douglas SD, Lai JP, et al. (2007). Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol 2:42–8
   PubMed Web of Science ®Google Scholar
• Wu D, Paul DJ, Zhao X, et al. (2009). A sensitive and rapid liquid chromatography–tandem mass spectrometry method for the quantification of the novel neurokinin-1R-antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational neuroAIDS research. J Pharm Biomed Anal 49:739–45
   PubMed Web of Science ®Google Scholar
• Yoder Graber AL, Ramirez J, Innocenti F, Ratain MJ. (2007). UGT1A1*28 genotype affects the in vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genom 17:619–27
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Stong JM, et al. (2008). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709–24
   PubMed Web of Science ®Google Scholar